Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Biosimilar PBS Listing: Cipla’s Adalicip® Biosimilar to AbbVie’s Humira® PBS-Listed

Jan 1, 2024

Cipla’s Adalicip®, developed by Alvotech (AVT02), biosimilar to AbbVie’s Humira® (adalimumab) has been listed on the PBS (General Pharmaceutical Benefits) in the 40mg/0.4mL dosage in syringes and pen devices.  It is reimbursed to treat various conditions, including Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

Cipla’s public summary document for Adalicip® was published on 27 October 2023, and it was considered at the July 2023 PBAC meeting.